BioSpace News Archive

The Parkinson’s Foundation today announced the recipients of nearly $1 million in community grants for Parkinson’s disease (PD) programs across the U.S.

Justera Health Ltd. (CSE: VTAL) (OTCQB: SCRSF) (formerly ScreenPro Security Inc.) (“Justera” or the “Company”) is pleased to announce it has completed the acquisition of Juillet Wellness Centre (“Juillet Wellness”), a wellness center located in Burnaby, British Columbia, as of July 24, 2023.

Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device and digital health platform company focused on diabetes and prediabetes, announced today the completion and positive results of its feasibility study for its implantable continuous glucose monitor technology for patients with Type 1 and Type 2 insulin-dependent diabetes.

BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) (“BioMark”) an advanced stage liquid biopsy company with a focus on hard-to-detect and treat cancers issued a statement today commenting on the recent market activity.

Illumina Inc. and Pillar Biosciences Inc., the pioneers of Decision Medicine™, today announced a strategic partnership to make Pillar’s suite of oncology assays commercially available globally as part of the Illumina portfolio of oncology products.

Better Therapeutics, Inc today announced that it issued 2,023,583 shares of its common stock under its At-The-Market program at an average price per share of $1.19.

Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2023 financial results on Tuesday, Aug. 8, 2023.

Nymox Pharmaceutical Corporation [OTC: NYMXF] (the “Company”) is pleased to announce today important new long-term clinical trial results from the Company’s 146 patient NX03-0040 NYMOZARFEX (TM) U.S. study for low grade localized prostate cancer.

Beckman Coulter Diagnostics, a clinical diagnostics leader, received FDA clearance for its new DxC 500 AU Chemistry Analyzer, an automated chemistry analyzer, expanding the company’s clinical chemistry offering and demonstrating ongoing commitment to product innovation in the in vitro diagnostic industry.

Mabwell announced that clinical trial data from phase I/II study for advanced solid tumor of Nectin-4-targeting ADC, and phase III study of Long-Acting Recombinant Human Serum Albumin/Human Granulocyte-Colony Stimulating Factor Fusion Protein will be presented orally and as a poster respectively at ESMO Congress 2023, which will be held in Madrid, Spain, from Oct. 20th to 24th, 2023.